[Recent options in drug therapy after solid organ transplantation].
Solid organ transplantation has shown improvement in patient and graft survival rates due to the development of immunosuppression in the last fifty years; however only the last two decades led to the development of new, baseline immunosuppressive drugs that avoid the unlikely side effects of calcineurin inhibitors, especially nephrotoxicity. The transplanted organ is foreign to the host and, therefore, it induces a complex immune response of the recipient. In this review, a brief outline of immune response is given, followed by the introduction of new immunosuppressive drugs acting via variant pathways. These are compounds which are already in use or becoming shortly available and are potential future alternatives for the calcineurin inhibitors. This paper highlights the role of co-stimulation blockade with belatacept and the recently even more intensively studied field of tolerance induction.
Semmelweis Egyetem, Általános Orvostudományi Kar Transzplantációs és Sebészeti Klinika Budapest. balazspocze@gmail.com
Balázs
B
Pőcze
Péter
P
Németh
Róbert
R
Langer
D000069594:Abatacept; D065095:Calcineurin Inhibitors; D006084:Graft Rejection / Q000276:immunology* / Q000517:prevention & control*; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D018796:Immunoconjugates / Q000276:immunology / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016377:Organ Transplantation; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
D065095:Calcineurin Inhibitors; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D000069594:Abatacept; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases